Biogen (BIIB) Depreciation & Amortization (CF) (2009 - 2026)

Biogen's Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $236.1 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 21.51% year-over-year to $236.1 million; the TTM figure through Jun 2026 stood at $842.9 million (up 13.25% YoY), while the FY2025 annual figure was $779.9 million, up 15.85% from the prior year.
• Depreciation & Amortization (CF) for Q2 2026 stood at $236.1 million, up from $204.4 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $236.1 million in Q2 2026, with the low at $112.3 million in Q1 2023.
• The 5-year median for Depreciation & Amortization (CF) is $153.2 million (2024), against an average of $161.5 million.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) declined 21.52% in 2023, then surged 46.24% in 2024.
• Biogen's Depreciation & Amortization (CF) stood at $119.8 million in 2022, then increased by 16.94% to $140.1 million in 2023, then surged by 31.33% to $184.0 million in 2024, then grew by 8.8% to $200.2 million in 2025, then advanced by 17.93% to $236.1 million in 2026.
• Business Quant data shows BIIB's Depreciation & Amortization (CF) at $236.1 million in Q2 2026, $204.4 million in Q1 2026, and $200.2 million in Q4 2025.